trial

Oxytocin and Social Cognition in Schizophrenia

NCTId NCT00884897
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 28 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2012-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
28 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2010-01
Primary completion
2012-01
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Oxytocin

Sponsors

University of Maryland, Baltimore CountyLead Sponsor
National Institute on Drug Abuse (NIDA)Collaborator

Investigators

2
Deanna L. Kelly, Pharm.D., BCPPPrincipal Investigator
Mary Lee, MDPrincipal Investigator

Sites

1 total
Catonsville, United States

Linked catalysts

1
Oxytocin and Social Cognition in Schizophrenia — primary completion2012-01

Facts & assertions

4 sourced
Enrollment
28
Phase
PHASE2
Primary Completion Date
2012-01
Status
COMPLETED
relationships
The graph out of here
drug
Oxytocin
drug
lead_sponsor
University of Maryland, Baltimore County
company
collaborator
National Institute on Drug Abuse (NIDA)
company
indication
Emotional Intelligence
indication
Schizophrenia
indication
Social Cognition
indication
investigator
Deanna L. Kelly, Pharm.D., BCPP
person
Mary Lee, MD
person